Results 1 to 10 of about 20,079 (290)
Varenicline for smoking cessation [PDF]
Expert Review of Neurotherapeutics, 2007 Varenicline is a selective alpha(4)beta(2) nicotinic acetylcholine receptor partial agonist and the first non-nicotine-containing medication developed with the sole purpose of treating nicotine addiction. To date, four published clinical trials have demonstrated the efficacy and safety of varenicline for smoking cessation in healthy adults who were ...
Serena Tonstad
+16 more sources
Varenicline: quantifying the risk [PDF]
Canadian Medical Association Journal, 2011 We agree that there is a lack of clarity in Singh and colleagues’ article; it is very difficult for readers to follow how the various assumptions and extrapolations have been made.[1][1] The rather alarming figure of a 72% increase in serious cardiovascular events has been picked up by the ...
Brian S. Alper
+23 more sources
Varenicline for Tobacco Dependence [PDF]
New England Journal of Medicine, 2008 A 57-year-old man with a 60-pack-year history visits his primary care provider because he wants to quit smoking. He has a history of stable coronary artery disease, peripheral vascular disease, and hypertension. He also has severe obstructive lung disease (forced expiratory volume in 1 second, 39% of the predicted value) with a progressive increase in ...
J. Taylor Hays, Jon O. Ebbert
openalex +4 more sources
Effects of varenicline on sympatho-vagal balance and cue reactivity during smoking withdrawal: a randomised placebo-controlled trial [PDF]
Tobacco Induced Diseases, 2016 Introduction Varenicline is an effective smoking cessation medication. Some concern has been raised that its use may precipitate adverse cardiovascular events although no patho-physiological mechanism potentially underlying such an effect has been ...
Helge Haarmann +7 more
doaj +3 more sources
Varenicline in the treatment of tobacco dependence
Neuropsychiatric Disease and Treatment, 2008 Karl Fagerström1, John Hughes21Smokers Information Centre, Fagerström Consulting AB, Berga Alle 1, 25452 Helsingborg, Sweden; 2University of Vermont, Burlington, Vermont, USAAbstract: Varenicline, a partial agonist of α4& ...
Karl Fagerström, John Hughes
doaj +5 more sources
Varenicline for smoking cessation: efficacy, safety, and treatment recommendations
Patient Preference and Adherence, 2010 Jon O Ebbert, Kirk D Wyatt, J Taylor Hays, Eric W Klee, Richard D HurtMayo Clinic College of Medicine, Rochester, MN, USAAbstract: Smoking is the leading preventable cause of morbidity and mortality in the US, and decreasing smoking prevalence is a ...
Jon O Ebbert +3 more
doaj +3 more sources
Utilization of varenicline among Kansas Medicaid enrollees. [PDF]
PLoS ONEBackgroundSmoking prevalence among Medicaid beneficiaries is twice that of privately insured adults, yet effective smoking cessation treatments remain underutilized.
Nathalia M Machado +3 more
doaj +2 more sources
Use of low-dose varenicline in hospitalized smokers: A case series low-dose varenicline in hospitalized smokers [PDF]
SAGE Open Medical Case ReportsNicotine replacement therapy is the primary medication used to treat tobacco dependence in hospitalized patients. Recent evidence shows that varenicline is more effective than nicotine replacement, but varenicline side effects limit its use in the ...
Rachael L. Joyner +3 more
doaj +2 more sources
Pilot safety evaluation of varenicline for the treatment of methamphetamine dependence [PDF]
Journal of Experimental Pharmacology, 2009 Todd Zorick1, Rajkumar J Sevak1, Karen Miotto1, Steven Shoptaw2,4, Aimee-Noelle Swanson2, Clayton Clement1, Richard De La Garza II1*, Thomas F Newton1*, Edythe D London1,3,41Departments of Psychiatry and Biobehavioral Sciences, 2Family Medicine ...
Todd Zorick +3 more
doaj +2 more sources